You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Micra™ AccelAV
Ambulatory AV synchronous pacing over time using a leadless ventricular pacemaker:
Larry A. Chinitz, M.D., FHRS, Mikhael F. El Chami, M.D., FHRS, et al.
Primary results from the AccelAV study
85.4% and stable through three months
82.6% with optimized programming
No major complications due to pacemaker syndrome
Listen now to the podcast on the Micra™ AccelAV study from Alphons Vincent, Medtronic Medical Affairs Director for Western Europe.
Alphons Vincent podcast - (04:06)
Alphons Vincent podcast, Medical Affairs Director - Western Europe. Ambalatory AV synchronous pacing over time using a leadless venticular pacemaker: Primary results from the AccelAV study.
More information (see more)
Less information (see less)
To report on the performance of the Micra™ AV leadless ventricular pacemaker with accelerometer-based algorithms that provide AV synchronous pacing.
Prospective, single-arm, multicenter, global study
- 152 subjects from 20 centers in the U.S. and Hong Kong were implanted with a Micra™ AV
– 54 with complete AV block and normal sinus function (primary analysis cohort)
- 20 with complete AV block, normal sinus function, and optimized programming (Optimized sub-study cohort)
which aims to review the underlying evidence, provide practical considerations for optimal use and patient selection for laeadless and extravascular CIED’s.
Read the Micra™ CED study published in the European Heart Journal. Real-world study showing the safety and efficacy of the Micra leadless VVI pacemaker vs transvenous pacemakers.
ESC Guidelines now recommend leadless pacing for defined patient populations.4
Includes independently published manuscripts not sponsored by Medtronic.
Chinitz LA, El-Chami MF, Sagi V, et al. Ambulatory AV synchronous pacing over time using a leadless ventricular pacemaker: Primary results from the AccelAV study. Heart Rhythm. Published online September 5, 2022.
Leick A. “Largest Reach” supporting data. June 2022. Medtronic Data on file
Clementy N, et al. Early Experience with a Leadless Ventricular Pacemaker Providing Atrioventricular Synchronous Pacing in the Real-World Setting: Results from the Micra AV Post-Approval Registry. Presented at HRS 2022 Scientific Sessions. April 30, 2022. San Fransico
Glikson, M. et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. October 2021. European Heart Journal.
Nippoldt D, Whiting J. Micra Transcatheter Pacing System Device Volume Characterization Comparison. November 2014. Medtronic data on file